首頁資訊腹部脂肪分布對(duì)2型糖尿病患者人體成分及胰島功能的影響

腹部脂肪分布對(duì)2型糖尿病患者人體成分及胰島功能的影響

來源：泰然健康網(wǎng) 時(shí)間：2024年12月10日 16:05

參考文獻(xiàn)/References:

[1] Sima A,Timar R,Vlad A,et al.Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients[J].Wien Klin Wochenschr,2014,126(11-12):335-340.DOI:10.1007/s00508-014-0530-8.
[2] Brunt EM.Pathology of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol,2010,7(4):195-203.DOI:10.1038/nrgastro.2010.21.
[3] Lafargue AL,Cabrales LB,Larramendi RM. Bioelectrical parameters of the whole human body obtained through bioelectrical impedance analysis[J].Bioelectromagnetics,2002,23(6):450-454.DOI:10.1002/bem.10034.
[4] Pietil?inen KH,Kaye S,Karmi A,et al. Agreement of bioelectrical impedance with dual-energy X-ray absorptiometry and MRI to estimate changes in body fat, skeletal muscle and visceral fat during a 12-month weight loss intervention[J].Br J Nutr,2013,109(10):1910-1916.DOI:10.1017/S0007114512003698.
[5] Fan JG,Jia JD,Li YM,et al.Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010:(published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166)[J].J Dig Dis,2011,12(1):38-44.DOI:10.1111/j.1751-2980.2010.00476.x.
[6] 劉德豐,陸強(qiáng),丁偉利,等.男性腹型肥胖患者內(nèi)臟脂肪面積與胰島素抵抗的相關(guān)性分析[J]. 中國綜合臨床, 2014,(7):724-726. DOI:10.3760/cma.j.issn.1008-6315.2014.07.019.
[7] Petta S,Amato MC,Di Marco V,et al.Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2012,35(2):238-247.DOI:10.1111/j.1365-2036.2011.04929.x.
[8] Kruger R,Shultz SP,McNaughton SA,et al.Predictors and risks of body fat profiles in young New Zealand European, Māori and Pacific women: study protocol for the women's EXPLORE study[J].Springerplus,2015,4:128.DOI:10.1186/s40064-015-0916-8.
[9] Subramanian V,Johnston RD,Kaye P,et al.Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2013,37(4):455-463.DOI:10.1111/apt.12198.
[10] Utzschneider KM,Kahn SE.Review:the role of insulin resistance in nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab,2006,91(12):4753-4761.DOI:10.1210/jc.2006-0587.
[11] Lim S,Oh TJ,Koh KK.Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders[J].Int J Cardiol,2015,201:408-414.DOI:10.1016/j.ijcard.2015.08.107.
[12] Bacchi E,Negri C,Targher G,et al.Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease(the RAED2 Randomized Trial)[J].Hepatology,2013,58(4):1287-195. DOI:10.1002/hep.26393.
[13] 譚擎纓, 姚佳琦,王秀景,等.腹腔內(nèi)臟脂肪面積與2型糖尿病及血清胰島素的相關(guān)研究[J]. 東南國防醫(yī)藥, 2015,(1): 12-15.DOI:10.3969/j.issn.1672-271X.2015.01.004.
[14] 陳蕾,賈偉平,項(xiàng)坤三,等.肥胖者胰島素抵抗與總體脂、局部體脂關(guān)系的研究[J].中華內(nèi)分泌代謝雜志,2001,17(5):276-279.DOI:10.3760/j.issn:1000-6699.2001.05.005.
[15] Abate N,Garg A,Peshock RM,et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM[J].Diabetes,1996,45(12):1684-1693.DOI:10.2337/diab.45.12.1684.
[16] Choe EY,Lee YH,Choi YJ,et al.Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes[J].J Gastroenterol Hepatol,2018,33(5):1082-1091.DOI:10.1111/jgh.14011.
[17] Klein S,Fontana L,Young VL,et al.Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease[J].N Engl J Med,2004,350(25):2549-2557.DOI:10.1056/NEJMoa033179.
[18] Th?rne A,L?nnqvist F,Apelman J,et al.A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding[J].Int J Obes Relat Metab Disord,2002,26(2):193-199.DOI:10.1038/sj.ijo.0801871.
[19] Mantatzis M,Milousis T,Katergari S,et al. Abdominal adipose tissue distribution on MRI and diabetes[J].Acad Radiol,2014,21(5):667-674.DOI:10.1016/j.acra.2014.01.009.
[20] Müller MJ,Lagerpusch M,Enderle J,et al.Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome[J].Obes Rev,2012,13(Suppl 2):6-13.DOI:10.1111/j.1467-789X.2012.01033.x.
[21] Lee J,Lee JY,Lee JH,et al.Visceral fat obesity is highly associated with primary gout in a metabolically obese but normal weighted population: a case control study[J].Arthritis Res Ther,2015,17:79.DOI:10.1186/s13075-015-0593-6.
[22] Kang SH,Cho KH,Park JW,et al.Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multi-frequency bioimpedance[J].Kidney Blood Press Res,2015,40(3):223-230.DOI:10.1159/000368498.
[23] 葛輝,陳君,孫毅明,等.廣州市健康體檢人群非酒精性脂肪肝患病情況及相關(guān)危險(xiǎn)因素分析[J]. 中華醫(yī)學(xué)雜志, 2016, 96(46):3706-3709.DOI:10.3760/cma.j.issn.0376-2491.2016.46.003.
[24] 徐蕓,王振豫,李繼昌,等.腹內(nèi)型肥胖與非酒精性脂肪肝的關(guān)系[J]. 中華肝臟病雜志,2001,9(2):124.DOI:10.3760/j.issn:1007-3418.2001.02.027.
[25] Byrne CD,Targher G.Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2014,34(6):1155-1161.DOI:10.1161/ATVBAHA.114.303034.
[26] 任穎,劉偉,陸廣華,等.2型糖尿病病人的內(nèi)臟脂肪性肥胖和胰島素抵抗[J].中國糖尿病雜志,2003,11(2):84-87.DOI:10.3321/j.issn:1006-6187.2003.02.003.

相似文獻(xiàn)/References:

[1]趙紫琴,雒瑢,田鳳石,等.替米沙坦對(duì)OLETF大鼠皮下和內(nèi)臟脂肪組織PPARγ表達(dá)的影響[J].國際內(nèi)分泌代謝雜志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
　Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,張翼飛,張志國,等.小檗堿改善代謝性疾病的腸道相關(guān)機(jī)制[J].國際內(nèi)分泌代謝雜志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
　Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹涵,曲伸.過氧化物酶體增殖物活化受體與非酒精性脂肪性肝病[J].國際內(nèi)分泌代謝雜志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
　Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[4]胡雅琴,包玉倩.維生素D對(duì)非酒精性脂肪性肝病的保護(hù)作用[J].國際內(nèi)分泌代謝雜志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
　Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[5]曹萌韋曉劉超.自噬與胰島β細(xì)胞功能及2型糖尿病[J].國際內(nèi)分泌代謝雜志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
　Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[6]劉艷田秀標(biāo) 韓穎.GLP-1受體激動(dòng)劑呈葡萄糖依賴性刺激胰島β細(xì)胞胰島素分泌的機(jī)制[J].國際內(nèi)分泌代謝雜志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
　Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(06):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[7]齊利琴,劉禮斌.GLP-1在2型糖尿病誘發(fā)的阿爾茨海默病治療中的作用[J].國際內(nèi)分泌代謝雜志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
　Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[8]聶秀玲,李明珍,孫麗榮.高尿酸血癥與非酒精性脂肪性肝病[J].國際內(nèi)分泌代謝雜志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
　Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(06):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[9]梅穩(wěn),向光大,盧俊顏,等.GDF11對(duì)ApoE-/-糖尿病小鼠內(nèi)皮依賴性血管舒張功能的作用[J].國際內(nèi)分泌代謝雜志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
　Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(06):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[10]殷俏,張?jiān)屏?郭淑芹,等.視黃醇結(jié)合蛋白4、超敏C反應(yīng)蛋白與糖尿病視網(wǎng)膜病變的關(guān)系[J].國際內(nèi)分泌代謝雜志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
　Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[11]李霞雷濤.鐵過載與代謝性疾病的關(guān)系[J].國際內(nèi)分泌代謝雜志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
　Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(06):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[12]韓亮吳凡陳廣.胎球蛋白在非酒精性脂肪性肝病和2型糖尿病中的作用[J].國際內(nèi)分泌代謝雜志,2018,38(06):419.[doi:10.3760/cma.j.issn.1673-4157.2018.06.015]
　Han Liang*,Wu Fan,Chen Guang.Roles of fetuins in non-alcoholic fatty liver disease and type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(06):419.[doi:10.3760/cma.j.issn.1673-4157.2018.06.015]
[13]呂梟銳龔鳳英.Hepassocin:一種新型的肝細(xì)胞因子[J].國際內(nèi)分泌代謝雜志,2019,39(05):332.[doi:10.3760/cma.j.issn.1673-4157.2019.05.011]
　Lyu Xiaorui,Gong Fengying.Hepassocin: a novel hepatokine[J].International Journal of Endocrinology and Metabolism,2019,39(06):332.[doi:10.3760/cma.j.issn.1673-4157.2019.05.011]
[14]扈若凡徐少勇沈涵景策賈愛華魚馨文邢影梁聲茹明潔姬秋和.非酒精性脂肪性肝病人群細(xì)胞角蛋白18 水平與2型糖尿病發(fā)病風(fēng)險(xiǎn)[J].國際內(nèi)分泌代謝雜志,2020,40(04):228.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
　Hu Ruofan,Xu Shaoyong,Shen Han,et al.Cytokeratin-18 level and the risk of type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(06):228.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
[15]沈友輝,杜斌.PAI-1引起2型糖尿病合并NAFLD小鼠肝臟炎性反應(yīng)和纖維化的機(jī)制研究[J].國際內(nèi)分泌代謝雜志,2021,41(02):110.[doi:10.3760/cma.j.cn121383-20200414-04038]
　Shen Youhui,Du Bin..Research of the effects of PAI-1 on inflammation and fibrosis in type 2 diabetic mice with NAFLD[J].International Journal of Endocrinology and Metabolism,2021,41(06):110.[doi:10.3760/cma.j.cn121383-20200414-04038]
[16]王慧,李忠淑.二甲雙胍聯(lián)合恩替卡韋治療2型糖尿病合并HBV感染并發(fā)NAFLD的療效分析[J].國際內(nèi)分泌代謝雜志,2022,42(02):124.[doi:10.3760/cma.j.cn121383-20200711-07031]
　Wang Hui,Li Zhongshu..Therapeutic effect of metformin combined with entecavir on type 2 diabetes mellitus complicated with HBV infection and NAFLD[J].International Journal of Endocrinology and Metabolism,2022,42(06):124.[doi:10.3760/cma.j.cn121383-20200711-07031]